Who are Digoxin immune fab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antizol, Cyanokit, Acetadote, multivitamin, Atropine/Neostigmine, Activated Charcoal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/digoxin-immune-fab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Digoxin immune fab — Competitive Intelligence Brief

Digoxin immune fab (Digoxin immune fab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidote; Immunoglobulin fragment. Area: Cardiovascular; Toxicology.

marketed Antidote; Immunoglobulin fragment Digoxin (cardiac glycoside) Cardiovascular; Toxicology Small molecule Live · refreshed every 30 min

Target snapshot

Digoxin immune fab (Digoxin immune fab) — National Institute on Aging (NIA). Digoxin immune fab binds to and neutralizes circulating digoxin, preventing its toxic effects by forming inactive complexes that are renally eliminated.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Digoxin immune fab TARGET	Digoxin immune fab	National Institute on Aging (NIA)	marketed	Antidote; Immunoglobulin fragment	Digoxin (cardiac glycoside)
Antizol	FOMEPIZOLE	Par Pharm Inc	marketed	Antidote [EPC]	Alcohol dehydrogenase	1997-01-01
Cyanokit	HYDROXOCOBALAMIN	Btg Intl	marketed	Antidote		1978-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	marketed	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
multivitamin	multivitamin	New York State Institute for Basic Research	marketed	Antidote [EPC]
Atropine/Neostigmine	Atropine/Neostigmine	Hadassah Medical Organization	marketed	Antidote combination; anticholinergic + cholinesterase inhibitor	Muscarinic acetylcholine receptors (atropine); acetylcholinesterase (neostigmine)
Activated Charcoal	Activated Charcoal	State University of New York - Upstate Medical University	marketed	Adsorbent antidote

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-21 — Acetadote · 8148356 · Formulation · US
2031-07-21 — Acetadote · 9327028 · Method of Use · US
2032-04-06 — Acetadote · 8722738 · Method of Use · US
2032-05-08 — Acetadote · 8747894 · Formulation · US
2032-05-08 — Acetadote · 9561204 · Method of Use · US
2032-05-08 — Acetadote · 9427421 · Formulation · US

Sponsor landscape (Antidote; Immunoglobulin fragment class)

National Institute on Aging (NIA) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Digoxin immune fab — Competitive Intelligence Brief. https://druglandscape.com/ci/digoxin-immune-fab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab